scispace - formally typeset
Search or ask a question
Institution

Keele University

EducationNewcastle-under-Lyme, United Kingdom
About: Keele University is a education organization based out in Newcastle-under-Lyme, United Kingdom. It is known for research contribution in the topics: Population & Stars. The organization has 11318 authors who have published 26323 publications receiving 894671 citations. The organization is also known as: Keele University.
Topics: Population, Stars, Health care, Galaxy, Planet


Papers
More filters
Journal ArticleDOI
TL;DR: A unified generic model for information which is referenced to two spatial dimensions and two temporal dimensions (database and event times) is discussed.
Abstract: Many applications of spatial information systems require not just spatial data handling but a unified approach to space and time. This paper begins by motivating this requirement with some examples, continues by identifying some of the key issues in this area and then discusses a unified generic model for information which is referenced to two spatial dimensions and two temporal dimensions (database and event times)

390 citations

Journal ArticleDOI
TL;DR: The studies on enzymes immobilized on ordered mesoporous solids and the need for careful studies in real applications are reviewed and the emerging applications of related biomolecule–mesoporous solid hybrids in other applications are noted.
Abstract: The discovery in the late 1990s of ordered, high surface area silicas with pore sizes of 5 nm and above opened the way to the study of well-defined biomolecule–mesoporous silica hybrids. In particular, it has been possible to immobilize a range of small to medium size enzymes, such as proteases, lipases and peroxidases, via physisorption, encapsulation and tethering on the internal surfaces of the solids. Use has also been made of silicas functionalized for this purpose. In many cases the immobilized enzymes are both active and re-usable. Here we review the studies on enzymes immobilized on ordered mesoporous solids and assess the need for careful studies in real applications. Furthermore, we note the emerging applications of related biomolecule–mesoporous solid hybrids in other applications, such as intracellular drug delivery and transfection technology.

390 citations

Journal ArticleDOI
TL;DR: This is the first user-friendly Negishi protocol capable of routinely cross-coupling all combinations of alkyl and aryl centers and the first time Pd-NHC (NHC=N-heterocyclic carbene) methodology has surpassed the related phosphine-ligated Negishi processes both in activity and use.
Abstract: We have developed the first user-friendly Negishi protocol capable of routinely cross-coupling all combinations of alkyl and aryl centers. The use of an easily synthesized, air stable, highly active, well-defined precatalyst PEPPSI-IPr (1; PEPPSI=pyridine-enhanced precatalyst preparation, stabilization and initiation; IPr=diisopropylphenylimidazolium derivative) substantially increases the scope, reliability, and ease-of-use of the Negishi reaction. All organohalides and routinely used pseudohalides were excellent coupling partners, with the use of chlorides, bromides, iodides, triflates, tosylates, and mesylates resulting in high yield of the coupled product. Furthermore, all reactions were performed by using general laboratory techniques, with no glove-box necessary as the precatalyst was weighed and stored in air. Utilization of this methodology allowed for the easy synthesis of an assortment of sterically encumbered biaryls and druglike heteroaromatics, demonstrating the value of the PEPPSI-IPr system. Furthermore, this is also the first time Pd-NHC (NHC=N-heterocyclic carbene) methodology has surpassed the related phosphine-ligated Negishi processes both in activity and use.

389 citations

Journal ArticleDOI
TL;DR: In this article, the mass-loss rate for oxygen-rich dust-enshrouded red supergiants in the Large Magellanic Cloud (LMC) was investigated.
Abstract: We present an empirical determination of the mass-loss rate as a function of stellar luminosity and effective tem- perature, for oxygen-rich dust-enshrouded Asymptotic Giant Branch stars and red supergiants To this aim we obtained optical spectra of a sample of dust-enshrouded red giants in the Large Magellanic Cloud, which we complemented with spectroscopic and infrared photometric data from the literature Two of these turned out to be hot emission-line stars, of which one is a definite B(e) star The mass-loss rates were measured through modelling of the spectral energy distributions We thus obtain the mass- loss rate formula log u M = −565 + 105 log(L/10 000 L� ) − 6 3l og(Teff/3500 K), valid for dust-enshrouded red supergiants and oxygen-rich AGB stars Despite the low metallicity of the LMC, both AGB stars and red supergiants are found at late spectral types A comparison with galactic AGB stars and red supergiants shows excellent agreement between the mass-loss rate as predicted by our formula and that derived from the 60 µm flux density for dust-enshrouded objects, but not for optically bright objects We discuss the possible implications of this for the mass-loss mechanism

389 citations

Journal ArticleDOI
TL;DR: The coexistence of type 2 diabetes mellitus and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent and associated with a higher risk of HF hospitalization, all‐cause and cardiovascular (CV) mortality.
Abstract: The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients) and associated with a higher risk of HF hospitalization, all-cause and cardiovascular (CV) mortality. The most important causes of HF in T2DM are coronary artery disease, arterial hypertension and a direct detrimental effect of T2DM on the myocardium. T2DM is often unrecognized in HF patients, and vice versa, which emphasizes the importance of an active search for both disorders in the clinical practice. There are no specific limitations to HF treatment in T2DM. Subanalyses of trials addressing HF treatment in the general population have shown that all HF therapies are similarly effective regardless of T2DM. Concerning T2DM treatment in HF patients, most guidelines currently recommend metformin as the first-line choice. Sulphonylureas and insulin have been the traditional second- and third-line therapies although their safety in HF is equivocal. Neither glucagon-like preptide-1 (GLP-1) receptor agonists, nor dipeptidyl peptidase-4 (DPP4) inhibitors reduce the risk for HF hospitalization. Indeed, a DPP4 inhibitor, saxagliptin, has been associated with a higher risk of HF hospitalization. Thiazolidinediones (pioglitazone and rosiglitazone) are contraindicated in patients with (or at risk of) HF. In recent trials, sodium-glucose co-transporter-2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have both shown a significant reduction in HF hospitalization in patients with established CV disease or at risk of CV disease. Several ongoing trials should provide an insight into the effectiveness of SGLT2 inhibitors in patients with HFrEF and HFpEF in the absence of T2DM.

389 citations


Authors

Showing all 11402 results

NameH-indexPapersCitations
George Davey Smith2242540248373
Simon D. M. White189795231645
James F. Wilson146677101883
Stephen O'Rahilly13852075686
Wendy Taylor131125289457
Nicola Maffulli115157059548
Georg Kresse111430244729
Patrick B. Hall11147068383
Peter T. Katzmarzyk11061856484
John F. Dovidio10946646982
Elizabeth H. Blackburn10834450726
Mary L. Phillips10542239995
Garry P. Nolan10447446025
Wayne W. Hancock10350535694
Mohamed H. Sayegh10348538540
Network Information
Related Institutions (5)
University of Manchester
168K papers, 6.4M citations

95% related

University of Birmingham
115.3K papers, 4.3M citations

94% related

University College London
210.6K papers, 9.8M citations

94% related

University of Bristol
113.1K papers, 4.9M citations

93% related

University of Oxford
258.1K papers, 12.9M citations

93% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202344
2022155
20211,473
20201,377
20191,178
20181,106